Trial Profile
ODIXa-DVT A Prospective, Randomized, Multinational, Multicenter, Partially Blinded, Parallel-Group, Open-Label Active Comparator Controlled Phase II Dose Finding and Proof of Principle Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium; Vitamin K antagonists
- Indications Deep vein thrombosis
- Focus Proof of concept; Therapeutic Use
- Acronyms ODIXa-DVT
- Sponsors Bayer
- 06 Feb 2009 Status changed to completed as reported by ClinicalTrials.gov.
- 06 Feb 2009 New source identitified and integrated (ClinicalTrials.gov).
- 18 Jul 2007 New trial record.